Arjuna Capital Has $1.88 Million Position in Haemonetics Co. (NYSE:HAE)

Arjuna Capital grew its holdings in shares of Haemonetics Co. (NYSE:HAEFree Report) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,004 shares of the medical instruments supplier’s stock after acquiring an additional 326 shares during the period. Arjuna Capital’s holdings in Haemonetics were worth $1,882,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Carmel Capital Partners LLC acquired a new stake in shares of Haemonetics in the 3rd quarter valued at about $30,000. Meeder Asset Management Inc. grew its stake in shares of Haemonetics by 65.2% in the 4th quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 135 shares during the period. State of Wyoming acquired a new stake in shares of Haemonetics in the 4th quarter valued at about $28,000. AdvisorNet Financial Inc grew its stake in shares of Haemonetics by 3,963.6% in the 3rd quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 436 shares during the period. Finally, Belpointe Asset Management LLC grew its stake in shares of Haemonetics by 65.5% in the 1st quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 180 shares during the period. 99.38% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Down 0.9 %

NYSE HAE traded down $0.70 during trading hours on Monday, hitting $73.50. The company’s stock had a trading volume of 31,927 shares, compared to its average volume of 414,387. Haemonetics Co. has a 52 week low of $73.02 and a 52 week high of $95.26. The company has a market capitalization of $3.73 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 1.89 and a beta of 0.34. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The company’s 50-day simple moving average is $83.19 and its two-hundred day simple moving average is $86.43.

Haemonetics (NYSE:HAEGet Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter last year, the firm earned $0.85 EPS. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. Research analysts anticipate that Haemonetics Co. will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on HAE shares. StockNews.com downgraded Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Barrington Research dropped their price target on shares of Haemonetics from $114.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd.

Check Out Our Latest Analysis on Haemonetics

About Haemonetics

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Recommended Stories

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.